Matt Rossen

Matt has over 20 years of commercial experience across a range of therapeutic categories, including CNS, sleep science, hematology, and oncology. Before joining Tarsus, Matt served as Vice President of Marketing for QED Therapeutics (a BridgeBio company), where he established the commercial infrastructure and led cross-functional launch planning efforts for Truseltiq, QED’s first approved therapeutic. Prior to QED, Matt served in roles of increasing responsibility at Jazz Pharmaceuticals, including as Marketing Director for Xyrem (sleep science), Head of Marketing for the Hematology portfolio, and as Senior Director of Business Development. Prior to Jazz, Matt worked at Pfizer across several commercial functions such as commercial operations, US and global marketing, and commercial development.

Matt holds his BA in Kinesiology and Human Physiology from the University of Colorado and obtained his MBA from New York University.